<SEC-DOCUMENT>0001213900-19-004592.txt : 20190321
<SEC-HEADER>0001213900-19-004592.hdr.sgml : 20190321
<ACCEPTANCE-DATETIME>20190321083023
ACCESSION NUMBER:		0001213900-19-004592
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190320
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190321
DATE AS OF CHANGE:		20190321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		19695953

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k032019_optimizerx.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>WASHINGTON, D.C. 20549<BR> </B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: center"><B>FORM 8-K</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B><BR>
<BR>
Date of Report (Date of earliest event reported): March 20, 2019<BR>
<BR>
<U>OptimizeRx Corporation</U><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">Nevada</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">000-53605</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">26-1265381</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 66%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">400 Water Street, Suite 200, Rochester,
    MI</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">48307</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Registrant&rsquo;s telephone number, including area code: <U>248.651.6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">___________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
        last report)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Emerging growth company&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60pt; text-align: left"><B>Item 8.01</B></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><B> Other Events</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 20, 2019, we issued a press release announcing results
and findings from our Drug Cost Survey. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form
8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60pt; text-align: left"><B>Item 9.01 </B></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits</B></TD>
</TR>               <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">99.1 </TD><TD>&nbsp;</TD><TD STYLE="text-align: justify"><A HREF="f8k032019ex99-1_optimizerx.htm">Press release, dated March 20, 2019</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 25%"><B>OptimizeRx Corporation</B></TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Douglas Baker</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Douglas Baker</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date: March 21, 2019</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><BR> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k032019ex99-1_optimizerx.htm
<DESCRIPTION>PRESS RELEASE, DATED MARCH 20, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 113px; width: 480px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>OptimizeRx Survey
Shows Providers Want to Engage with Patients on Drug Costs for Adherence and Improved Care </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><I>More than 600
providers polled, showing awareness of patients&rsquo; increasing drug costs but missed opportunity to support patient financial
savings </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black; background-color: white"><B>ROCHESTER,
Mich., </B></FONT><B><FONT STYLE="color: Black">(March 20, 2019) &mdash;</FONT></B><FONT STYLE="color: Black"> OptimizeRx Corp.
(NASDAQ: OPRX), a leading digital health messaging platform for the pharmaceutical industry, released its full results and findings
from its Drug Cost Survey. The survey focused on prescription drug costs, yielding insights into physician perspectives on the
affordability of prescription drugs and patient adherence to prescription regimens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Released in partnership with Jane Sarasohn-Kahn,
a health economist, advisor and industry influencer from THINK-Health LLC and Health Populi, the full survey findings concluded
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>The cost of prescription drugs is
on the mind of physicians and patients alike. </B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt; color: Black">The
                                         vast majority of patients raise the issue of the cost of prescription drugs with their
                                         doctors</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt; color: Black">Most
                                         physicians (86 percent) are comfortable discussing health care costs with patients and
                                         over 90 percent believe they have a role to play in discussing healthcare costs with
                                         patients</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt; color: Black">73
                                         percent of physicians feel patient&rsquo;s responsibility for cost is important when
                                         making a prescribing decision</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Physicians believe a variety of factors
that lead to unfilled prescriptions, including: </B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt; color: Black">The
                                         high costs of prescribed medicines (70 percent)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt; color: Black">Intolerable
                                         or unpleasant side effects (45 percent)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt; color: Black">A
                                         patient&rsquo;s&nbsp;desire not to take pills (34 percent)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt; color: Black">Patients
                                         already taking too many pills (31 percent) </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>While doctors believe they understand
the reasons for patients not filling prescriptions,&nbsp;too few physicians track when patients haven&rsquo;t filled that script:
</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD><FONT STYLE="color: Black">Only
                                         5 percent of doctors &ldquo;always&rdquo; track an unfilled prescription and 18 percent
                                         &ldquo;usually&rdquo; do so</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD><FONT STYLE="color: Black">Taken
                                         together, that means that three-quarters of doctors are&nbsp;<I>not&nbsp;</I>tracking
                                         unfilled prescriptions</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&ldquo;According to a recent study,
lack of medication adherence costs the U.S. health system as much as $528 billion in the context of possible consequences, illnesses,
and deaths that result from non-optimized medication therapy,&rdquo; said Sarasohn-Kahn. &ldquo;Patients are at-risk of contributing
to this public health challenge when they avoid filling prescriptions. There are strategies that can help to risk-manage this
in order to lower care costs and improve peoples&rsquo; outcomes. We need to address this through an ecosystem-wide, holistic
lens.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt; color: Black">Added Miriam Paramore,
president of OptimizeR</FONT><FONT STYLE="color: Black">x: <FONT STYLE="font-size: 10pt">&ldquo;Shared decision-making between
patients and prescribers will be more important than ever, and the cost-conversations and discussions around access will be central
in the patient-prescriber relationship. We&rsquo;re working tirelessly to fill this communication gap so that providers can successfully
address cost challenges to support consumer loyalty and trust.&rdquo; </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">The survey was the first to be executed
through OptimizeMDs, a multi-specialty physician panel created by OptimizeRx to improve the effectiveness of digital communication
between pharma/life sciences and physicians at the point-of-care. Initial results were released at the Healthcare Information
Management Systems Society (HIMSS) 2019 conference. OptimizeRx plans to facilitate a corollary consumer survey to gauge their
perspectives on financial discussions, prescription affordability and medication adherence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">The full position paper and survey results
can be downloaded at info.optimizerx.com/survey-results. For more information on OptimizeRx, visit www.optimizerx.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><I>Conducted between January 9 and 14,
2019, the survey included responses from 642 physicians across a variety of specialties, practice and/or hospital sizes and locations
across the United States. It was the first to be executed through&nbsp;OptimizeMDs, a multi-specialty physician panel created
by OptimizeRx to improve the effectiveness of digital communication between pharma/life sciences and physicians at the point-of-care.
OptimizeMDs is one of the brand support services available to pharmaceutical manufacturers.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>About OptimizeRx</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black; background-color: white">OptimizeRx&reg;
(NASDAQ: OPRX), a digital health company,&nbsp;connects&nbsp;pharmaceutical companies to patients and providers, offering greater
affordability, adherence and brand awareness at the point-of-care. As the nation&rsquo;s largest point-of-prescribe promotional
platform for the pharmaceutical industry,&nbsp;OptimizeRx&nbsp;provides a direct channel for pharma companies to communicate with
healthcare providers right within their workflow and also directly to patients. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black; background-color: white">The cloud-based
solution supports patient adherence to medications and better healthcare outcomes with real-time access to financial assistance,
prior authorization, education and critical clinical information.&nbsp;OptimizeRx&nbsp;provides more than half of the ambulatory
patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest, and directly
via its mobile communications platform.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">For more information, follow the company
on&nbsp;Twitter,&nbsp;LinkedIn&nbsp;or visit&nbsp;www.optimizerx.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Important Cautions Regarding Forward
Looking Statements</B><BR>
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as
amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be
used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or
revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements
are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual
results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks
and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation,
competition and other material risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>OptimizeRx Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Doug Baker, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (248) 651-6568 x807</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black">dbaker@optimizerx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Media Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Nicole Brooks, Innsena Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">(Tel) 860-800-2344</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black">nicolebrooks@innsena.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Investor Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Ron Both, CMA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (949) 432-7557</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black">oprx@cma.team</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !Q > # 2(  A$! Q$!_\0
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M  F^F?\ /&Y_[X'^->BJ]*WQ&O,CHF574JP!5A@@]Q7DURBQ74T:?=21E7Z
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M?]A*+^2U[4.G/6O-+KP5KLOQ,77$MXC8B]27?YPW;0!GC\*4&"/3*XCXM_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
